Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Michael Dugan"'
Autor:
Vipasha Sood, Argenis Rodas-González, Stephanie Lam, Óscar López-Campos, Jose Segura, Timothy Schwinghamer, Michael Dugan, John Basarab, Jennifer Aalhus, Manuel Juárez
Publikováno v:
Foods, Vol 11, Iss 4, p 518 (2022)
This study used 1076 crossbred steers to evaluate the effects of calf-fed and yearling-fed beef production systems, implant strategies (with and without implants), and their interactions on the primal tissue composition (lean and fat components) of i
Externí odkaz:
https://doaj.org/article/ece2afb0273e42d08536f70e140af575
Autor:
Kenneth B. Simons, Humayun J. Chaudhry, Xiaomei Pei, Aaron Young, Michael Dugan, Katie Arnhart
Publikováno v:
Journal of Medical Regulation. 107:57-64
There are 1,018,776 licensed physicians in the United States and the District of Columbia, representing a physician workforce that is 20% larger than it was a decade ago, according to data from 2020 compiled by the Federation of State Medical Boards
Autor:
Priya Kumthekar, Michael Youssef, Nicholas Blondin, Amir Azadi, David Piccioni, Michael Glantz, Jose Carillo, Akanksha Sharma, Nicholas Avgeropoulos, Sherif Makar, Barbara Blouw, Anna Natasha, Deanna Fisher, Lan Huynh, John Peters, Mariko Matsutani, Edgar Sales, Nathan Sweed, Michael Dugan, Santosh Kesari
Publikováno v:
Neuro-Oncology. 24:vii4-vii5
INTRODUCTION Patients with leptomeningeal metastasis (LM) have limited treatment options and a poor outcome. However, they may benefit from targeted therapy. LM patients with HER2-positive primary breast cancer treated with IT trastuzumab demonstrate
Autor:
Kaitlyn Armijo, Nathan Sweed, Steven Hsiao, Tony Pircher, Mikayla Marrin, Leslie Cho, Kelly Kreitzburg, Barbara Blouw, Deanna Fisher, Michael Dugan, Santosh Kesari
Publikováno v:
Neuro-Oncology. 24:vii145-vii145
BACKGROUND Pineal parenchymal tumors of intermediate differentiation (PPTID) account for 21% to 54% of pineal parenchymal tumors and may be complicated by cerebrospinal dissemination (most commonly at time of reoccurrence; up to 4-10 years post resec
Autor:
Steven Hsiao, Tony Pircher, Nathan Sweed, Kaitlyn Armijo, Mikayla Marrin, Leslie Cho, Michael Dugan, Santosh Kesari
Publikováno v:
Neuro-Oncology. 24:vii142-vii142
BACKGROUND Metastatic involvement of the CSF by non-CNS neoplasms surpasses that of primary brain tumors, although conventional glioblastoma (GBM) can occasionally be identified in the CSF. Here, we apply Biocept’s CNSide test to examine a patient
Autor:
Scott A. Steingard, Katie Arnhart, Humayun J. Chaudhry, Aaron Young, Michael Dugan, Xiaomei Pei
Publikováno v:
Journal of Medical Regulation. 105:7-23
There are 985,026 physicians with Doctor of Medicine (MD) and Doctor of Osteopathic Medicine (DO) degrees licensed to practice medicine in the United States and the District of Columbia, according to physician census data compiled by the Federation o
Autor:
Richard W. Troughton, Marc D. Samsky, Frank W. Rockhold, Robert J. Mentz, Dianne Leloudis, Linda M. Mundy, Adrian F. Hernandez, Justin A. Ezekowitz, Carmine G. De Pasquale, Michael Dugan, Eileen O'Meara, Andrew P. Ambrosy, Jyostna Garg, Yee Weng Wong, Javed Butler, Gregory D. Lewis
Publikováno v:
Circulation. Heart Failure
Background: Iron deficiency (ID) has a prevalence of ≈40% to 50% among patients in heart failure (HF) with reduced ejection fraction and is associated with worse prognosis. Several trials demonstrated that intravenous ferric carboxymaltose leads to
Publikováno v:
Cancer Research. 82:PD4-03
Introduction. Breast cancers that metastasize to the central nervous system (BrM) and progress to leptomeningeal disease (LMD) are commonly HER2 amplified. Triple negative breast cancer (TNBC) also may also acquire HER2 amplification and/or copy numb
Autor:
Michael Dugan, Deanna Fisher, Priya Kumthekar, Barbara Blouw, Julie Ann Mayer, Nicholas Blondin, Amir Azadi
Publikováno v:
Neuro Oncol
INTRODUCTION Leptomeningeal Disease (LMD) occurs in 5% of breast cancer patients. Diagnosing LMD remains challenging. Current standard of care has limited sensitivity and is inadequate for monitoring treatment response. Biocept’s CNSide™ is a pro